540 related articles for article (PubMed ID: 15807982)
1. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
2. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
3. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
[TBL] [Abstract][Full Text] [Related]
4. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
5. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical product development technologies based on the biopharmaceutical classification system.
Jain D; Pathak D; Pathak K
Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834
[TBL] [Abstract][Full Text] [Related]
7. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
Dokoumetzidis A; Macheras P
Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
9. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
Golovenko NIa; Borisiuk IIu
Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
[TBL] [Abstract][Full Text] [Related]
10. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
12. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
13. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
17. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
18. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
19. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products.
Alt A; Potthast H; Moessinger J; Sickmüller B; Oeser H
Eur J Pharm Biopharm; 2004 Jul; 58(1):145-50. PubMed ID: 15207548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
